AstraZeneca shares fall on report of potential China probe fallout
AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior executives at its China unit could be implicated in the largest insurance fraud case in the country's pharma sector in years.
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...
AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...
Europe's STOXX 600 eked out minor gains on Tuesday led by gains in industrials as investors assessed a slew of downbeat ...
Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price ...
The AstraZeneca (LSE: AZN) share price is in freefall at the moment. Yesterday (5 November), it fell 8.4%. Since late August, it has plummeted nearly 25%. So, what’s going on here? And has the share ...
Britain's benchmark FTSE 100 edged lower on Tuesday, hurt by AstraZeneca's fall on a potential China probe, while investors ...
Bullish option flow detected in AstraZeneca (AZN) with 5,692 calls trading, 5x expected, and implied vol increasing almost 3 points to 33.14%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback